UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.28 Million Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 25.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,267 shares of the medical instruments supplier’s stock after selling 11,916 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in LeMaitre Vascular were worth $3,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LMAT. Driehaus Capital Management LLC boosted its position in shares of LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after buying an additional 90,573 shares during the period. F M Investments LLC acquired a new position in shares of LeMaitre Vascular during the second quarter worth about $7,443,000. Nicholas Investment Partners LP acquired a new position in shares of LeMaitre Vascular during the second quarter worth about $3,900,000. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after buying an additional 36,850 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in shares of LeMaitre Vascular by 15.7% during the third quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after buying an additional 35,383 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Performance

LMAT stock opened at $100.69 on Friday. The stock’s 50 day simple moving average is $97.47 and its 200 day simple moving average is $89.33. LeMaitre Vascular, Inc. has a fifty-two week low of $52.88 and a fifty-two week high of $109.58. The company has a market cap of $2.26 billion, a P/E ratio of 55.02, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LMAT. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. Barrington Research increased their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. JMP Securities increased their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.